Astellas has partnered with a Boston startup working on “miniproteins,” Endpoints News reported in an exclusive on October 20. No terms, targets or deal structure were disclosed, and no second outlet had the story at the time of this edition, so the partnership itself is carried as Endpoints reported it and graded C. Astellas has form here: in 2023 it paid Cullgen $35 million upfront for targeted protein degrader options that could exceed $1.9 billion in total. For a deal story without numbers, the existence of the signature is the whole event, and it stays in this roundup until a company disclosure gives it structure.
A Cochrane review of 93 studies has found that pharmaceutical industry gifts and payments to prescribers are strongly linked to what the researchers called “inappropriate prescribing,” such as treatments patients may not need or that could cause harm, along with higher prescribing costs and higher prescription volume, PharmaVoice reported on October 20. Advertising and education visits pointed the same way with less certain evidence. The authors could not establish causation but said they were confident the pattern was real, and found that institutional conflict-of-interest policies at places like Harvard- and Stanford-affiliated hospitals were probably associated with better prescribing. A quarter of physicians surveyed did not even know whether their institution had such policies. The piece also noted a JAMA Network Open study finding that 64 resolved anti-kickback cases between 2000 and 2025 carried a median penalty equal to just 2.2 percent of US revenue from the implicated drugs, the kind of arithmetic that lets companies treat penalties as a cost of doing business.
Endpoints News returned to Lilly’s retatrutide on October 21 with a piece on its sleep apnea positioning ahead of the obesity launch expected next year. The numbers it discusses trace to the TRIUMPH-1 results published in the New England Journal of Medicine on September 29, which this site covered in the October 13 roundup: in the 243-patient sleep apnea basket nested in the 2,339-patient trial, breathing interruptions fell by 22.9, 34.3 and 31.7 events per hour across the 4, 9 and 12 mg doses against 9.9 on placebo, with the 9 mg dose beating placebo by 24.7 events per hour. There is no new trial data; the story is the commercial framing, retatrutide as a potential sleep apnea therapy to follow Zepbound’s approved use there, ahead of the planned first-quarter 2027 approval request.
On policy, a bipartisan group of lawmakers is urging the FDA to close a peptide loophole, STAT reported on October 20, in a letter that targets compounded peptides operating around the agency’s drug rules. The item is carried at headline level from the feed; the letter’s specific asks and the FDA’s response are not yet on the record. Mark Cuban’s Cost Plus Drug Company wants to crack open the market for rare disease treatments, STAT reported on October 21, an access push that extends the Cuban playbook from generics into the high-price, low-volume world. And STAT profiled Immatics, the German biotech with big cancer ambitions, now at the point where it needs to get a medicine approved, a useful marker for the TCR cell therapy field as the first registrational data approach.